After Three-Year Lull, Alcon Cited For Professional Ad Violations
This article was originally published in The Pink Sheet Daily
Executive SummaryDDMAC has sent five letters since 2003 for violations in promotional materials directed at health care professionals.
You may also be interested in...
The eighth enforcement letter from FDA in a decade cites the company for unjustified claims about its seasonal allergic rhinitis drug, Patanase.
Promotion is not a reminder ad since the ophthalmic’s indication is depicted graphically, a notice of violation letter contends. Citation about advertising and promotional infractions is the second in about a year for Alcon Research.